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HIV Controllers are rare individuals who spontaneously control HIV replication in the absence of 48 
antiretroviral therapy. To identify parameters of the CD4 response that may contribute to viral 49 
control, rather than merely reflect a persistently low viremia, we compared the T helper profile in 50 
two groups of patients with more than 10 years of viral suppression: HIV Controllers from the 51 
ANRS CO18 cohort (n=26) and efficiently treated patients (n=16). Cells specific for 52 
immunodominant Gag and CMV peptides were evaluated for the production of 10 cytokines and 53 
cytotoxicity markers, and were also directly quantified ex vivo by MHC class II tetramer staining. 54 
HIV Controller CD4+ T cells were characterized by a higher frequency of IFN-γ production, 55 
perforin+/CD107a+ expression, and polyfunctionality in response to Gag peptides. While IL-4, 56 
IL-17, and IL-21 production did not differ between groups, treated patients cells produced more 57 
IL-10 in response to Gag and CMV peptides, pointing to persistent negative immunoregulation 58 
after long-term antiretroviral therapy. Gag293 tetramer-positive cells were detected at high 59 
frequency (0.12%) and correlated positively with IFN-γ producing CD4+ T cells in the Controller 60 
group (R=0.73; P=0.003). Tetramer-positive cells were fewer in the HAART group (0.04%) and 61 
did not correlate with IFN-γ production, supporting the notion of a persistent immune dysfunction 62 
in HIV-specific CD4+ T cells of treated patients. In conclusion, HIV Controllers maintained a 63 
population of highly efficient Th1 effectors directed against Gag in spite of a persistently low 64 





HIV Controllers are rare individuals who spontaneously control HIV replication in the absence of 69 
antiretroviral therapy. They can maintain a viral load below the detection threshold of standard 70 
assays (< 50 copies HIV RNA/ml plasma) for decades and show a very low risk of progression 71 
to AIDS (4, 23). Converging evidence indicate that HIV Controllers have developed particularly 72 
efficient cellular antiviral responses, that can maintain an active control of the infected target cell 73 
population in the long-term. HIV Controller CD8+ T cells have the capacity to efficiently suppress 74 
HIV replication in autologous CD4+ T cells in vitro (48, 64) and are thought to play a key role in 75 
HIV control (reviewed in (1, 3, 15, 28)). 76 
 77 
The contribution of CD4+ T cells to HIV control remains more debated (9, 34, 45, 56). HIV 78 
Controllers maintain a central memory CD4+ T cell population with a remarkable proliferative 79 
capacity in response to HIV antigens, which is associated with an efficient secretion of IL-2 (19, 80 
26, 58, 81) and with the inactivation of pro-apoptotic molecules (73). A high proliferative capacity 81 
of HIV-specific CD4+ T cells can also persist in patients who were treated very early in the 82 
primary infection stage (62). However, most of the treated patients with good CD4 proliferation 83 
and IL-2 secretion failed to control HIV replication upon therapy interruption (34, 40), indicating 84 
that IL-2 responses alone were insufficient to mediate HIV control. Several studies have since 85 
suggested that the CD4 response pattern in HIV Controllers is qualitatively distinct from that of 86 
efficiently treated patients, and is not just the consequence of a very low antigenemia. Controller 87 
CD4+ T cells have proven to be more "polyfunctional" than those of treated patients, indicating a 88 
greater capacity to produce the cytokines/chemokines IL-2, IFN-γ, TNF-α and MIP-1β 89 
simultaneously, in the circulation (16, 19, 36, 52, 58), as well as in mucosal tissues (20). The 90 
expression of the negative costimulatory molecule CTLA-4 is lower on HIV-specific CD4+ T cells 91 
of Controllers than on those of treated patients, suggesting that TCR-dependent activation may 92 
be more efficient (39). In addition, we recently reported the presence of a CD4+ T cell population 93 
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with a high avidity for immunodominant Gag peptides in HIV Controllers, indicating the capacity 94 
to respond to minimal amounts of virus (74). All these factors may promote efficient CD4 helper 95 
function, which could then sustain a high quality CD8 response. Mouse models of chronic viral 96 
infections indicate that CD4+ T cell help is needed for efficient antiviral CD8 responses, and that 97 
CD4+ T cell depletion causes virus-specific CD8+ T cells to adopt an exhausted phenotype 98 
similar to that seen in progressive HIV infection (78). A key issue remains to pinpoint, among the 99 
spectrum of possible CD4+ T cell functions, those that may contribute to HIV control. 100 
 101 
The T helper differentiation of HIV-specific CD4+ T cells, defined by the pattern of cytokines 102 
produced upon antigenic stimulation, has been characterized in viremic and treated patients, but 103 
has not been fully explored in HIV Controllers. The expanding diversity of T helper types, 104 
including Th1, Th2, Th17, and Tfh follicular helpers, as well as the recent recognition of plasticity 105 
in T helper differentiation (reviewed in (22, 82, 85)) warrant further investigation of this issue. 106 
Production of the Th1 cytokine IFN-γ has been consistently detected in specific CD4+ T cells 107 
from all categories of HIV infected patients, but its contribution to the suppression of HIV 108 
replication remains unclear, with high IFN-γ responses found at both extremities of the 109 
progression spectrum, in HIV Controllers as well as in highly viremic patients (16, 20, 55, 58). 110 
HIV-specific CD4+ T cells producing IL-17 have been detected in acute HIV infection, but were 111 
few or absent afterwards in viremic and treated patients (5, 84). There have been no reports so 112 
far of the presence of HIV-specific Th17 cells in HIV Controllers. However, HIV infection is 113 
known to have a clear impact on the total Th17 population, which is preferentially depleted in the 114 
blood and intestinal mucosa of progressor patients (5, 42, 46, 49, 59), but not of HIV Controllers 115 
(12, 67). Th17 depletion in progressor patients may play a role in the chronic immune activation 116 
characteristic of HIV disease, through a loss of cytokines that promote the regeneration of 117 
epithelial barriers, leading to compromised mucosal integrity and allowing the crossing of 118 
inflammatory bacterial components (16).  119 
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The cytokine IL-21, which is produced almost exclusively by CD4+ T cells, promotes B cell 120 
memory, through the induction of B cell isotype class switching and survival (75). Models of 121 
chronic viral infection in mice have revealed the importance of IL-21 in promoting the antiviral 122 
functions of CD8+ T cells, in addition to its role in humoral responses (18, 79). Recent studies 123 
have highlighted the possible contribution of this cytokine to HIV control, with the findings that IL-124 
21 in plasma correlates positively with CD4 counts (33) and that IL-21 secreted by HIV-specific 125 
CD4+ T cells could induce a cytotoxic differentiation program with perforin induction in cognate 126 
CD8+ T cells (11). Whether the frequency of IL-21 producing specific CD4+ T cells differs in HIV 127 
Controllers as compared to other patient groups remains debated, with one study showing an 128 
increase in the Controller group (11), and two studies showing equivalent or lower levels (77, 129 
83). However, in the population of patients with detectable viremia, the persistence of IL-21 130 
producing CD4+ T cells is clearly associated with a beneficial outcome, as indicated by an 131 
inverse correlation with viral load (11, 83), and a positive correlation with the frequency of IL-2+ 132 
specific CD8+ T cells (77). 133 
 134 
We set to characterize the T helper effector profile of HIV Controller CD4+ T cells, by measuring 135 
the expression of 10 cytokines, chemokines, or cytotoxicity markers (perforin, CD107a) by 136 
intracellular staining. In addition, we implemented the direct detection of HIV-specific CD4+ T 137 
cells by MHC class II tetramer staining ex vivo, to obtain information on their frequency and 138 
phenotype without the perturbations associated with in vitro activation. While the use of MHC 139 
class I tetramers to identify HIV-specific CD8+ T cells is widespread, few studies have made use 140 
of the MHC class II tetramer reagents, mostly due to the lower frequency of HIV-specific CD4+ T 141 
cells and to the complexity in producing stable recombinant HLA-DR molecules. These hurdles 142 
are being overcome, through the use of magnetic concentration or high speed acquisition of 143 
CD4+ T cells, as well as progress in HLA class II expression strategies (13, 43, 47). Two pioneer 144 
studies found that CD4+ T cells specific for Gag p24 epitopes could be detected by class II 145 
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tetramer staining in HIV infected patients under therapy, at low but detectable frequencies 146 
(between 10-4 to 10-5), and that short-term therapy interruption led to a rebound in the frequency 147 
of tetramer-positive (Tet+) CD4+ T cells (68, 69). In contrast, prolonged viremia ultimately led to 148 
the loss of the Tet+ population, suggesting the physical depletion of Gag-specific CD4+ T cells 149 
in progressor patients (69). We measured the frequency of Tet+ CD4+ T cells in HIV Controllers, 150 
to test the notion that these rare patients could maintain a large population of HIV-specific CD4+ 151 
T cells in spite of low antigenemia. The Gag p24 protein has been shown to harbor 152 
immunodominant peptides that can be recognized by up to half of HIV-infected patients, due in 153 
part to the promiscuous binding of these peptides to diverse HLA-DR and DQ molecules (35, 38, 154 
60). By amplifying p24 Gag-specific CD4+ T cells in primary cell lines, we showed previously 155 
that the peptide spanning amino acids 293-312 (Gag293) induced a memory response in >90% 156 
of HIV Controllers and treated patients who expressed at least one of 7 common HLA-DR alleles 157 
(74). This broad recognition gave us the opportunity to compare the frequency and phenotype of 158 
Gag293-specific cells by MHC class II tetramer staining in a cohort of HIV Controllers and in 159 
patients who had received efficient antiretroviral therapy in the long-term. Both groups were 160 
characterized by viral suppression (<50 copies of HIV-1 RNA/ml) for over 10 years, allowing a 161 
comparative analysis of CD4 responses in two situations of persistently low antigenemia.  162 
 163 
Comparison of these two groups of patients showed that the HIV Controller status was 164 
associated with a higher frequency of Th1 effectors, but not of Th2, Th17, or IL-21+ effectors. 165 
The only cytokine with a higher production in the treated patient group was IL-10, suggesting the 166 
presence of a negative immunoregulatory state in the CD4+ T cell compartment in spite of 167 
pharmacological viral suppression. MHC class II tetramer analysis showed that Gag293-specific 168 
CD4+ T cells persisted at high frequency (10-3) in HIV Controllers, but also in a subset of treated 169 
patients. The frequency of Tet+ cells correlated positively with IFN-γ production in the Controller 170 
group but not in the treated patient group, indicating high CD4+ T cell functionality in HIV 171 
 8 
Controllers, and persistent immune dysfunction of the HIV-specific CD4+ T cell compartment in 172 
patients treated in the long-term. 173 
 174 
 175 
MATERIALS AND METHODS 176 
Patients  177 
HIV Controllers (HIC group; n=26) were recruited through the CO18 cohort set up by the Agence 178 
Nationale de Recherche sur le SIDA et les hépatites virales (ANRS). In the present study, HIV 179 
controllers were defined as HIV-1 infected patients who had been seropositive for >10 years, 180 
had received no antiretroviral treatment, and for whom >90% of plasma viral load measurements 181 
were undetectable by standard assays. All HIV controllers included in the present study had 182 
current viral loads <40 copies/mL. The group of efficiently treated patients (HAART group; n=16) 183 
had received antiretroviral therapy for a minimum of 10 years and showed long term viral 184 
suppression with viral loads <40 copies of HIV RNA/mL. Treated patients were recruited through 185 
the ANRS SEROCO-HEMOCO cohort, the Raymond Poincaré Hospital (Garches, France), and 186 
the Bicêtre Hospital (Le Kremlin-Bicêtre, France). The healthy donor group (HD group; n=12) 187 
consisted in anonymous healthy individuals who donated blood at the Etablissement Français 188 
du Sang (EFS, Paris, France). The study was promoted by ANRS under number EP36 and 189 
approved by the Comité de Protection des Personnes IDF VII under number 05-22. All 190 
participants gave written informed consent prior to blood sampling. 191 
 192 
Whole blood phenotyping 193 
Expression of the activation markers HLA-DR and CD38 were evaluated in CD4+ T cell subsets 194 
by phenotyping in 100 µl whole blood. Red blood cells were lyzed with the Lyse/Fix buffer (BD 195 
Biosciences, San Jose, CA) and remaining leukocytes were labeled with the following 196 
antibodies: anti-CD4-PE-Texas Red (Beckman Coulter, Fullerton, CA), anti-CD3-APC-eFluor 197 
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780, anti-CD38-PerCP-eFluor710, anti-HLA-DR-PE-Cy7, (eBioscience, San Diego, CA), anti-198 
CD45RA-Horizon V450 and anti-CCR7-Alexa Fluor 647 (AF647, BD Biosciences). Fluorescence 199 
was collected on a 9 color CyAn flow cytometer (Beckman Coulter) using the Summit version 4.3 200 
software. 201 
 202 
Intracellular cytokine staining assay (ICS)  203 
HIV-specific stimulation was performed by adding a 20-mer Gag peptide (Gag293-312, Gag263-204 
282, or Gag161-180) at 5 µg/ml to 2x106 freshly isolated PBMC, in the presence of antibodies to 205 
the costimulatory molecules CD28 (0.5 µg/mL) and CD49d (0.5 µg/ml). CMV-specific stimulation 206 
was performed by adding an optimal pp65 20-mer peptide chosen in function of the HLA-DR 207 
genotype of the patient, as described in (74). Negative controls consisted in 2x106 unstimulated 208 
PBMC. Positive controls were obtained by stimulating 2x106 PBMC with 1 µg/mL of the 209 
superantigen Staphylococcal Enterotoxin B (Toxin Technology, Sarasota, FL). Cells were 210 
stimulated for 14 h in the presence of the secretion inhibitors monensin (2 µM) and brefeldin A (3 211 
µg/ml). Cells were harvested, split in three, and stained for surface antigens with the following 212 
antibodies: anti-CD107a-FITC (BD Biosciences), anti-CD3-APC-eFluor780 (eBioscience), and 213 
anti-CD4-PE-Texas-Red (Beckman Coulter). The Aqua Live/dead viability dye (Invitrogen) was 214 
added to exclude dead cells. Cells were fixed and permeabilized using a fix/perm kit 215 
(eBioscience) according to the manufacturer's instructions. Intracellular cytokines staining was 216 
detected with anti-IL21-PE, anti-IL4-PE, anti-MIP-1β-PE, anti-IFNγ-PE-Cy7, anti-IL2-APC (all 217 
from BD Biosciences), anti-IL17-AF488, anti-IL10-eFluor450, anti-TNFα-eFluor450 (all from 218 
eBioscience), and anti-Perforin-PerCP clone B-D48 (Gen-PROBE). Fluorescence was collected 219 
on a CyAn flow cytometer, with a minimum of 250,000 events collected in the lymphocyte gate 220 
for each sample. 221 
 222 
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Flow cytometry data analysis 223 
Flow cytometry data was analyzed using the FlowJo software (version v8.8.7; Tree Star, 224 
Ashland, OR). Intracellular cytokine production was evaluated in the live (Aqua-) CD3+, CD4+ 225 
lymphocyte gate. The percentage of cytokine producing CD4+ T cells was determined after 226 
subtracting the percentage of cytokine-positive events in unstimulated controls. Responses 227 
below the level of 0.01% cytokine-producing cells after background subtraction were considered 228 
negative. 229 
 Polyfunctionality was assessed for a first panel of 5 functions that included the production 230 
of IFN-γ, IL-2, MIP-1β, TNF-α, and CD107a. The second panel included 4 functions, 231 
corresponding to the production of IFN-γ, IL-10, IL-17, and IL-21. For each panel, the 232 
combinations of all boolean gates were generated in Flowjo, and the data was converted in 233 
Microsoft Excel to the matrix SPD format. The data was then analyzed and graphically 234 
represented using the SPICE software version 5.21, downloaded from http://exon.niaid.nih.gov. 235 
The threshold for cytokine positivity was 0.01%. Comparison of distributions was performed 236 
using a Student's T test and a partial permutation test as described (61). 237 
 238 
MHC class II tetramer labeling 239 
At initiation of the study, HIV Controllers and treated patients were genotyped for HLA-DRB1. 240 
Patients were included in the tetramer study if their genotype matched at least one of the 6 HLA-241 
DRB1 alleles available for MHC class II tetramer studies. This panel allowed the analysis of 242 
≥70% of Caucasian patients (10). PE-labeled tetramers for the DRB1*0101, DRB1*0301, 243 
DRB1*1501 and DRB5*0101 alleles were obtained through the NIH Tetramer Facility at Emory 244 
University. HLA-DRB1*0401, DRB1*0701, and DRB1*1101 biotinylated monomers were 245 
produced in insect cell cultures as previously described (44, 51). Monomers were loaded with 246 
0.2 mg/ml peptide by incubation at 37 °C for 72h in the presence of 2.5 mg/ml n-octyl-b-D-247 
glucopyranoside and 1mM Pefabloc SC (Sigma-Aldrich). Peptide-loaded monomers were 248 
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tetramerized using APC- or PE-conjugated streptavidin (eBioscience). To each tetramer loaded 249 
with an HIV-1 Gag or a CMV pp65 peptide corresponded a control tetramer loaded with the 250 
CLIP peptide. 251 
 CD4+ T cells specific for the Gag293 peptide FRDYVDRFYKTLRAEQASQE (spanning 252 
amino acids 293-312 in HIV-1 Gag) were detected by ex vivo MHC class II tetramer labeling for 253 
all the patients included in the tetramer study. CD4+ T cells specific for CMV pp65 were 254 
detected with tetramers loaded with an optimal peptide chosen in function of the HLA-DR 255 
genotype of the patient, as previously described (74). The CMV peptides used corresponded to 256 
amino acids 41-55, 177-191, 281-295, 489-507, and 509-523 within the pp65 protein. 257 
 For each MHC class II tetramer labeling, 6 x 106 PBMC were incubated with 4 µg/ml PE-258 
conjugated tetramer for 90 min at +4°C in PBS with 1% BSA and 10 mM sodium azide. Surface 259 
marker antibodies CD3-AF780-APC and CD38-PerCP-eFluor710 (from eBioscience), CD45RA-260 
V450 Horizon, CD8-FITC, CD14-FITC, CD19-FITC, and CCR7-AF647 (all from BD 261 
Biosciences), CD4-PE-Texas Red (Beckman Coulter), and the Aqua Live/Dead viability dye 262 
were added for the last 20 min of labeling. When APC-conjugated tetramers were used, CCR7-263 
PE (BD Biosciences) was used instead of CCR7-AF647. All events were acquired on a CyAn 264 
flow cytometer at an average speed of 1,000 events/s and were analyzed using the Flowjo 265 
software. The percentage of tetramer-positive (Tet+) cells was measured in the live (Aqua-), 266 
CD3+, CD4+, CD8-, CD14-, CD19- gate. Negative controls consisted in identical samples 267 
labeled with HLA-DR matched tetramers loaded with the CLIP peptide. The percentage of 268 
Gag293-specific Tet+ cells was computed by subtracting the percentage of CLIP Tet+ cells from 269 
that of Gag293 Tet+ cells. We verified that CD4+ T cells from healthy donors matched for HLA-270 
DRB1 gave minimal staining (≤0.01%) with Gag293 tetramers. Due to limiting blood samples, 271 




Statistical analysis 275 
Statistical analyses were performed with the GraphPad Prism 5.0 software, using nonparametric 276 
statistical tests in all cases. Differences in variables between groups were analyzed with the 277 
Mann-Whitney U Test. Correlations were analyzed with Spearman's coefficient R. All significant 278 
differences between groups (P<0.05) were reported on data plots. 279 
 280 
 281 
RESULTS     282 
Immune activation of CD4+ T cells in HIV Controllers and treated patients 283 
We set to compare CD4+ T cell phenotype and functions in two groups of HIV-1-infected 284 
patients characterized by long-term control of HIV infection (Table 1). HIV Controllers (HIC 285 
group, n=26) had shown a spontaneous control of HIV replication for over 10 years, while 286 
treated patients (HAART group, n=16) had received efficient antiviral therapy that led to 287 
pharmacological control of HIV for over 10 years. Patients in both groups had undetectable viral 288 
load by standard assays (<40 copies HIV-1 RNA/ml plasma). Both groups were also comparable 289 
in terms of patient age (median: 52 years in the HIC group vs. 49 years in the HAART group), of 290 
the estimated duration of HIV-1 infection (median of 18 years in both groups), of CD4+ T cell 291 
counts (median: 754/mm3 in the HIC group vs. 765/mm3 in the HAART group), and of CD4+ T 292 
cell percentages (median: 53.6% in the HIC group vs. 49.9% in the HAART group). The treated 293 
patients had a median CD4 nadir of 227 cells/mm3, which was slightly higher than that reported 294 
for historical controls in observational cohorts (17, 41), and may have been a factor in the 295 
efficient immune reconstitution in these patients (80). The similarly high CD4+ T cell counts in 296 
the HIC and HAART groups at the time of study ensured that immune differences due to the 297 
homeostatic response to CD4 lymphopenia were minimal. 298 
 Immune activation of CD4+ T cells, as measured by the combined expression of HLA-DR 299 
and CD38, did not differ significantly between the HIC and HAART groups (Table 2). Analyses of 300 
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the percentage of HLA-DR+ CD38+ cells in the naive (Nv), central memory (CM), and effector 301 
memory (EM) CD4+ T cell subsets defined by the CD45RA and CCR7 markers did not reveal 302 
significant differences either (Table 2). However, both HIC and HAART CD4+ T cells showed 303 
signs of immune activation when compared to those of healthy blood donors (HD). In particular, 304 
expression of HLA-DR and CD38 was significantly increased in the CD4+ EM compartment of 305 
both patients groups as compared to the HD group (P=0.01 for HIC vs. HD; P=0.0005 for 306 
HAART vs. HD; Table 2). Thus, there were signs of persisting immune activation in HIV 307 
Controllers and treated patients, in spite of the long duration of viral suppression and the 308 
relatively high CD4+ T cell counts in both groups. 309 
 310 
Th1 differentiation of Gag-specific CD4+ T cells in HIV Controllers 311 
To determine the T helper phenotype of Gag-specific CD4+ T cells, we analyzed their cytokine 312 
production pattern by intracellular staining. Responses were measured to three peptides 313 
(Gag293, Gag263, and Gag161) that induce immunodominant CD4 responses in a majority of 314 
HIV-1 infected patients (35, 38, 60, 74). The panel of cytokines analyzed included those typical 315 
of Th1 cells (IFN-γ, TNF-α, MIP-1β), Th2 cells (IL-4), and Th17 cells (IL-17). IL-21 was included 316 
as a marker of Th17 and recirculating Tfh cells. IL-2 was included to detect cells with good 317 
proliferative capacity and IL-10 to detect cells with immunoregulatory function. The combination 318 
of total perforin expression (clone D48) and of the degranulation marker CD107a was used to 319 
detect CD4+ T cells with cytotoxic potential. Negative controls consisting in healthy donor cells 320 
stimulated with Gag peptides are reported in supplementary figure S1. As seen in representative 321 
examples (Fig. 1A), CD4+ T cells that produced both IFN-γ and TNF-α, or IFN-γ and IL-2, could 322 
be detected in HIV Controllers, while IFN-γ and IL-4, or IFN-γ and IL-17, stemmed from separate 323 
producer cell populations. Examples of unstimulated controls are reported in supplementary 324 
figure S2. 325 
 326 
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Quantitation of intracellular cytokine production in responses to the 3 immunodominant Gag 327 
peptides showed that only IFN-γ production and perforin/CD107a expression were significantly 328 
increased in the HIC group as compared to the HAART group (P= 0.0012 and P=0.03, 329 
respectively) (Fig. 1B). The trends for higher IL-2 and IL-17 production in the HIC group did not 330 
reach statistical significance. It was however interesting that IL-17-secreting HIV-specific CD4+ 331 
T cells could be detected at high levels in a subset of HIV Controllers, given that these cells 332 
appear exceedingly rare in progressor patients (5, 84). IL-4 remained undetectable in the 333 
majority of patients of both groups, indicating that HIV-1 infection did not generally promote a 334 
Th2 differentiation pattern. However, IL-4 could be detected at significant levels in a few patients 335 
(Fig. 1A, upper right plot). IL-21 production could be high in a few patients but did not differ 336 
significantly between the two groups. Intriguingly, IL-10 was the only cytokine that showed a 337 
higher expression in the HAART group than in the HIC group (P=0.027), suggesting a 338 
dampening of effector responses by this immunoregulatory cytokine in treated patients. Taken 339 
together, these findings indicated that HIV-specific CD4+ T cells from Controllers were 340 
characterized by a clear Th1 differentiation profile, the presence of effector cells with cytotoxic 341 
potential, and the occasional occurrence of Th17 differentiation. 342 
 343 
Since certain MHC class I alleles are strongly associated with HIV control (1, 3, 15, 28), we 344 
examined the possible influence of the HLA B genotype on the level of Gag CD4 responses. 345 
HLA B typing was performed for all HIV Controllers and 10 of the treated patients (Table 1). The 346 
percentages of patients carrying the protective HLA alleles B57 and B27 differed significantly 347 
between the two groups (HIC: 65 % B57+ or B27+; HAART: 10% B57+ or B27+; P=0.0036), as 348 
expected. For further analysis, HIV Controllers were subdivided in two subgroups ("B57+ or 349 
B27+" versus "B57- and B27-") that were compared for cytokine responses to Gag peptides. We 350 
did not detect significant differences for the 8 cytokines analyzed nor for perforin/CD107a 351 
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expression, suggesting that the HLA B genotype was not a major determinant of the HIV-specific 352 
CD4 response. 353 
 354 
Immunoregulatory profile of Gag-specific and CMV-specific CD4+ T cells in long-term 355 
treated patients 356 
Analysis of CD4 responses at the single peptide level provided the opportunity to compare 357 
patient responses to the same epitope. The three immunodominant Gag peptides analyzed were 358 
all able to induce diverse cytokine responses in HIV infected patients (Fig. 2A and 2C). Gag293 359 
induced significantly more IFN-γ in the HIC than in the HAART group (P=0.02). Gag161 showed 360 
a trend for increased IFN-γ and TNF-α induction (P=0.052 and P=0.061) and caused increased 361 
perforin/CD107a expression in the HIC group (P=0.03). In contrast, the Gag263 peptide did not 362 
appear associated with the induction of Th1 effector responses (IFN-γ or Perforin/CD107a), but 363 
rather showed non-significant trends for increased IL-17 induction in the HIC group and 364 
increased IL-10 induction in the HAART group. These observations suggested that the T helper 365 
profile of Gag-specific CD4+ T cells depended on the type of patient but also, possibly, on the 366 
nature of the recognized epitope. 367 
 368 
As controls, responses to optimal peptides derived from the CMV matrix phosphoprotein pp65 369 
were tested with the same cytokine panel (Fig. 2B and 2D). The T helper pattern of pp65 370 
responses was mostly Th1, with a predominant production of IFN-γ, TNF-α, and MIP-1β in both 371 
the HIC and HAART groups, and equivalent cytokine production levels in both groups of 372 
patients. The one significant difference concerned IL-10 production, which again proved to be 373 
higher in the HAART group (P=0.003). Thus, patient treated in the long term showed signs of a 374 
dampened CD4 response to both HIV and CMV through the synthesis of IL-10. Treated patients 375 
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also showed a concomitant decrease of Th1 effectors directed against HIV but not CMV. In 376 
contrast, HIV Controllers maintained efficient Th1 effector responses to both viruses. 377 
 378 
Higher polyfunctionality of Gag-specific CD4+ Th1 cells in HIV Controllers 379 
Polyfunctionality, i.e. the capacity to produce multiple cytokines simultaneously, was first 380 
analyzed for a combination of 5 markers (CD107a, IFN-γ, IL-2, MIP-1β, and TNF-α) expressed 381 
predominantly in Th1 cells. This analysis was carried out for Gag293-specific cells, since these 382 
could be detected in the majority of patients. Among Gag293-specific CD4+ T cells, 383 
monofunctional cells were the most abundant, both in the HIC and HAART group (Fig. 3A). 384 
However, the fraction of polyfunctional cells expressing 2 to 4 markers was higher in the HIC 385 
group than in the HAART group, the difference being significant for bifunctional cells (P<0.05). 386 
Gag293-specific cells expressing all of the 5 markers together were not detected. Detailed 387 
analysis of the different marker combinations (Fig. 3B) highlighted the presence of peak of tri-388 
functional cells co-expressing IFN-γ, IL-2, and TNF-α that appeared characteristic of HIV 389 
Controllers. 390 
 391 
Polyfunctionality of Gag293-specific CD4+ T cells was analyzed for a second panel comprising 392 
the 4 cytokines IFN-γ, IL-10, IL-17, and IL-21 (Fig. 3C). The production of these 4 cytokines was 393 
almost mutually exclusive, with a low frequency of bifunctional cells, and an absence of tri- and 394 
quadri-functional cells. The slightly higher fraction of bi-functional cells in the HAART group 395 
appeared due to the co-synthesis of IL-10 and IL-17 in a subpopulation of Gag293-specific cells 396 
(Fig. 3D). Among monofunctional cells, the proportion of IFN-γ and IL-17 producing cells was 397 
higher in the HIC group, while that of IL-10 producing cells was higher in the HAART group. 398 
Thus, analysis of the Gag293-specific response supported the notion of persistent CD4 effectors 399 
in HIV Controllers, and of negative CD4 immunoregulation in treated patients. The fact that IFN-γ 400 
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and IL-17 were produced by distinct cells in HIV Controllers indicated that Gag293-specific cells 401 
had either a Th1 or a Th17 differentiation, but were not of the mixed Th1/Th17 phenotype. 402 
Similarly, few of the Th17 cells simultaneously produced IL-21, a cytokine that has been 403 
associated with the reinforcement of Th17 differentiation (76). Thus, a significant fraction of Th1 404 
cells from HIV Controllers were polyfunctional, but their Th17 cells appeared monofunctional. 405 
 406 
Higher frequency of Gag293-specific cells In HIV Controllers as determined by MHC class 407 
II tetramer staining 408 
We characterized Gag293-specific CD4+ T cells by MHC class II tetramer staining, in order to 409 
directly measure their frequency ex vivo. We focused the analysis on the Gag293 peptide, which 410 
could be loaded onto 6 different tetramers (HLA DRB1*0101, DRB1*0401, DRB1*0701, 411 
DRB1*1101, DRB1*1501, and DRB5*0101) due to its promiscuous binding to HLA-DR 412 
molecules (38). A minimum of 6x106 PBMC was used per tetramer labeling, in order to ensure 413 
the detection of low frequency specific CD4+ T cells with a sensitivity threshold of 0.001%. The 414 
percentage of Gag293 tetramer positive (Tet+) cells was minimal in CD4+ T cells of healthy 415 
blood donors (≤0.01%), but could reach up to 0.5-1% in both treated patients and HIV 416 
Controllers, as shown on representative examples (Fig. 4B). Thus, CD4 responses to this single 417 
immunodominant Gag peptide could reach high frequencies, even though the amount of Gag 418 
antigen present in patients was minimal (VL<40 copies in both groups). 419 
 420 
Comparison of both patient groups (Fig. 5A) showed a higher frequency of Gag293 Tet+ cells in 421 
HIV Controllers, with a median value of 0.12% of CD4+ T cells in the HIC group versus 0.04% in 422 
the HAART group (P<0.05). However, we noted a wide variation in Tet+ frequencies in the 423 
HAART group, with some of the treated patients showing as many Gag293 specific cells as the 424 
best responders in the Controller group. A similar phenomenon was observed when testing 425 
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tetramers loaded with optimal CMV pp65 peptides, with a trend towards lower responses in the 426 
HAART group (P=0.1), but with a high individual variability (Fig. 5B). 427 
 428 
The distribution of CD4+ T cell subsets based on the CD45RA and CCR7 markers was analyzed 429 
in the Tet+ populations (Fig. 5C and D). The Gag293 Tet+ population had a mixed phenotype, 430 
with a predominant central memory subset (CM, CD45RA- CCR7+) in the HIC as well as in the 431 
HAART groups, and a lower but detectable effector memory subset (EM, CD45RA- CCR7-). 432 
Highly differentiated effectors (CD45RA+ CCR7-) were too few to be quantified, while a fraction 433 
of Tet+ cells appeared phenotypically naive (CD4R5A+ CCR7+) (not shown). These cells also 434 
predominantly expressed CD27, raising the possibility of a reversion of Gag-specific CD4+ T 435 
cells to a fully naive phenotype. The phenotype of the CMV Tet+ population was also mixed, 436 
with a trend toward more CM and less EM in the HAART group as compared to that of the HIC 437 
group, though it did not reach statistical significance (P=0.13 and P=0.07, respectively). 438 
Expression of the costimulatory marker CD27 was high in the CM Tet+ population specific for 439 
Gag293, both in the HIC and the HAART group (median of 82.2% and 71.4%, respectively). 440 
CD27 expression was lower in the EM Tet+ population (median of 57.4% and of 49.2%), as 441 
expected, but still relatively high, indicating that approximately half of the EM Tet+ cells 442 
corresponded to a transitional memory population (Fig. 5E). Expression of CD27 in the CMV 443 
Tet+ population was comparable to that seen in the Gag293-specific population (Fig. 5F). Thus, 444 
CD27 expression was maintained in specific CD4+ T cells of both HIV Controllers and patients 445 
treated in the long-term, indicating of preserved costimulatory capacity and lack of immune 446 
exhaustion. 447 
 448 
The activation status of the Tet+ populations could not be evaluated with the HLA-DR marker, 449 
because anti-HLA-DR antibodies cross-reacted with some of the tetramer reagents. 450 
Interestingly, the CD38 activation marker showed a trend for higher expression in Gag293 Tet+ 451 
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cells of HIV Controllers as compared to those of treated patients, with a P value close to 452 
significance in the CM Tet+ subset (P= 0.057; Fig. 5G). CD38 expression did not differ 453 
significantly in the CMV Tet+ populations between the two groups, though again high CD38 454 
expression was noted for a few HIV Controllers (Fig. 5H). These findings suggested a possible 455 
increase of specific CD4+ T cell activation for a subset of HIV Controllers. However, there were 456 
no signs of massive activation nor of immune exhaustion in the Tet+ populations. 457 
 458 
Functional impairment of Gag293-specific cells in treated patients 459 
We then compared the frequencies of Gag293-specific CD4+ T cells detected physically (by 460 
class II tetramer binding) and functionally (by intracellular cytokine staining). Interestingly, the 461 
percentage of Tet+ cells and that of IFN-γ+ cells correlated positively in the HIC group (R=0.73, 462 
P=0.003) but not in the HAART group (R=0.33, P≥0.05) (Fig. 6A and 6B). The median ratio 463 
(IQR) of IFN-γ producing cells to Tet+ cells was of 0.28 (0.21 - 0.63) in the HIC group and 0.06 464 
(0.00 - 0.43) in the HAART group, indicating that the functional response of Tet+ cells from 465 
HAART patients was minimal. Similar analyses for other cytokines did not yield significant 466 
correlations, with the exception of a positive association between Gag293 Tet+ and IL-17-467 
producing cells observed in the HIC group (R=0.72, P=0.02) but not in the HAART group (Fig. 468 
6C and 6D). Taken together, these findings suggest that the vast majority Gag293-specific cells 469 
present in long-term treated patients fail to produce IFN-γ upon antigenic restimulation, pointing 470 
to an impaired Th1 response. In contrast Gag293-specific cells from HIV Controllers maintain an 471 




HIV Controller responses to immunodominant Gag peptides were characterized by the 476 
persistence of highly differentiated Th1 cells with effector functions, as indicated by a higher 477 
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frequency of IFN-γ secreting cells and of CD4+ T cells with degranulation capacity. The 478 
correlation between Gag293-specific cells detected by MHC class II tetramer staining and IFN-γ 479 
secretion indicated that about one fourth of Gag-specific CD4+ T cells maintained effector 480 
function, even though the amount of Gag antigen driving effector responses was minimal in vivo. 481 
In contrast, patients treated in the long term, who had equally low antigenemia, showed a 482 
downregulation of Gag-specific CD4 effector responses, as indicated by a lower frequency of 483 
cells with IFN-γ secretion or degranulation capacity, and a lower frequency of Gag293-specific 484 
cells detected by class II tetramer staining. In support of this notion, Gag-specific CD4+ T cells 485 
that persisted in treated patients showed signs of functional downregulation, as indicated by 486 
increased IL-10 secretion and the failure of Gag293-specific cells to produce IFN-γ upon 487 
restimulation. Thus, the Gag-specific response was maintained in a persistent effector state in 488 
HIV Controllers, while it appeared subjected to negative immunoregulation in treated patients. 489 
 490 
The differentiation of Gag-specific CD4+ T cells from HIV Controllers proved to be predominantly 491 
Th1, rather than Th2, Th17, or Tfh. A bias towards a Th1 effector response fits with the expected 492 
pattern for an efficient response against an intracellular pathogen such as HIV (85), but it should 493 
be noted that Th1 differentiation alone cannot account for viral control, since IFN-γ+ CD107a+ 494 
Th1 effectors are also abundant in viremic patients (16, 25, 55). Rather, it is the capacity to 495 
maintain a functional Th1 effector population in a situation of very low antigenemia that appears 496 
characteristic of HIV Controllers. The comparison with a group of patients treated efficiently in 497 
the very long term (more than 10 years) was instrumental in highlighting this difference, since 498 
other studies indicate that patients treated for a shorter period of time maintain a degree of Th1 499 
effector function, as indicated by detectable IFN-γ+ specific CD4+ T cells with degranulation 500 
capacity (2, 50). The long duration of treatment in the present study may also account for a 501 
degree of recovery of IL-2 responses in the HAART group, and the lack of a significant 502 
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difference in IL-2 production with the Controller group. Consistent with this notion, a recent 503 
comparison of patients treated efficiently for less than 3 years and more than 10 years showed 504 
that prolonged therapy further improved CD4 proliferative responses, while IFN-γ production by 505 
CD4+ T cells remained minimal (24). Thus, patient treated in the very long term show the 506 
expected signature of a resolved viral infection with antigen clearance, with a reappearance of 507 
IL-2 secreting memory CD4+ T cells with proliferative capacity and a loss of effector functions 508 
(25). HIV Controllers provide an exception to this pattern, as they appear to maintain both IL-2 509 
secretion and effector functions in the long-term in spite of minimal antigenemia. Early studies 510 
have provided evidence for a preserved central memory CD4+ T cell compartment with 511 
remarkable proliferative and IL-2 secretion capacities in HIV Controllers (19, 26, 58, 81). The 512 
notion of advanced effector differentiation has emerged in studies of CD8+ T cell responses in 513 
HIV Controllers, with the realization that these rare patients harbored HIV-specific CD8+ T cell 514 
with highly efficient antiviral functions, associated with an increased loading of perforin and 515 
granzyme B within cytotoxic granules (27, 29, 48, 64). The present study suggests that 516 
advanced effector differentiation also persists in the CD4+ T cell compartment of HIV 517 
Controllers. The presence of a CD107+ perforin+ CD4+ T cell population raises the possibility 518 
that Gag-specific CD4+ T cells may have direct cytotoxic potential and may contribute to the 519 
elimination of infected cells, a property that has been documented in certain chronic viral 520 
infections such as CMV (2, 8) and that characterizes CD4+ T cell clones from rhesus macaques 521 
able to control SIV infection (63). A recent study suggests that cytolytic CD4+ T cells may well 522 
play a role in the early control of HIV replication, with the finding that expansion of HIV-specific 523 
CD107a+ CD4+ T cells in the acute stage is associated with a lower viral setpoint (70). 524 
 525 
It was interesting that IL-17 production could be induced by Gag peptides in about half of the 526 
HIV Controllers, even though the difference with the HAART group did not reach significance. 527 
Previous studies have shown that HIV-specific Th17 cells are exceedingly rare in viremic and 528 
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treated patients, except during the acute infection stage (5, 84). The detection of Gag-specific 529 
Th17 cells in HIV Controllers is consistent with the preservation of the total Th17 population in 530 
the blood and the intestinal mucosa of these patients (12, 67), while Th17 cells are preferentially 531 
depleted in other patient groups (5, 42, 46, 49, 59). The presence of Gag-specific Th17 effectors 532 
may have beneficial effects, by contributing either directly or indirectly to HIV control and by 533 
helping maintain the integrity of mucosal surfaces. On the other hand, the activation of Th17 534 
effectors may also foster the low-grade inflammatory condition that persists in HIV Controllers (6, 535 
30, 58), with possible deleterious consequences such as increased susceptibility to 536 
cardiovascular disease in the long term (14). Analysis of polyfunctionality showed that most of 537 
IL-17+ CD4+ T cells in HIV Controllers did not produce IFN-γ, indicating the presence of typical 538 
Th17 cells, rather cells of the mixed Th1Th17 phenotype. We cannot rule out that Th17 cells 539 
produced other cytokines that were not tested in the same panel as IL-17, such as IL-2 or TNF-540 
α, but we noted that these cells did not produce IL-21, suggesting low polyfunctionality. The γc 541 
family cytokine IL-21, when produced by Th17 cells, acts in an autocrine fashion to amplify and 542 
stabilize IL-17 production, via the activation of the transcription factor STAT3 (76). The lack of 543 
bifunctional IL-17+ IL-21+ cells suggests that Th17 differentiation may be only transient, 544 
reinforcing the notion that the predominant helper differentiation pattern is rather Th1 in HIV 545 
Controllers. 546 
 547 
The MHC class II tetramer analysis showed that the population of HIV-specific CD4+ T cells 548 
persisted at relatively high levels in peripheral blood in the HIV Controller group, with a median 549 
of 0.12% CD4+ T cells directed against the single Gag293 peptide. Of note, this number is a 550 
minimal estimate, given that Gag293 can be presented by other HLA-DR alleles than those 551 
studied, and also by HLA-DQ molecules (35, 38). The finding of a high frequency of Tet+ cells in 552 
HIV Controllers supports the notions that HIV-specific CD4+ T cells are spared from depletion in 553 
situations of controlled viremia, and that a persistently active cellular response sustains the pool 554 
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of specific cells. The frequency of Gag293-specific cells was significantly lower in treated 555 
patients, though it was intriguing that it could remain as high as in Controllers for a few 556 
individuals. Two studies have shown that the frequency of Tet+ Gag-specific CD4+ T cells are 557 
generally low in treated patients and can rebound upon short-term therapy interruption, with a 558 
shift towards a more effector differentiation pattern accompanying the resumption of viral 559 
replication (68, 69). We cannot rule out that some of the treated patients may have undergone 560 
blips in viral replication that would have escaped detection but would have been sufficient to 561 
stimulate the expansion of specific cells. However, we did not detect a higher proportion of Tet+ 562 
cells with an effector memory phenotype in patients with a higher frequency of Tet+ cells (not 563 
shown). Rather, central memory cells predominated in the Tet+ populations, both in the HAART 564 
and HIC group, consistent with a low antigenemia. A possibility is that HIV-specific central 565 
memory cells may expand in some of the patients treated in the long-term, which would be 566 
consistent with a partial recovery of proliferative responses (24, 71). Importantly, increased Tet+ 567 
frequency did not correlate with increased IFN-γ secretion frequency in the HAART group, while 568 
it did so in the HIC group. Thus, Gag293-specific cells appeared to differ functionally, if not 569 
phenotypically, between the two groups, with a persistence of Th1 effector function in HIV 570 
Controllers. A caveat of this interpretation is that we did not directly detect cytokine production 571 
within the Tet+ population, due to a reduced sensitivity of Tet+ cell detection after intracellular 572 
cytokine staining. However, since the frequency of IFN-γ producer cells was minimal in treated 573 
patients, it is reasonable to assume that in these patients the vast majority of Tet+ cells would 574 
fail to produce IFN-γ upon restimulation with the Gag293 peptide. 575 
 576 
Several reasons may account for the persistence of an effector function in HIV Controllers but 577 
not in patients treated in the long term. A straightforward explanation could be the capacity of 578 
HIV Controller memory CD4+ T cells to reactivate upon encounter with very low amounts of viral 579 
antigens. Indeed, we recently reported that a subset of CD4+ T cells with a high avidity for the 580 
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Gag293 peptide could be detected exclusively in primary CD4+ T cell lines derived from HIV 581 
Controllers and not in those from treated patients (74). The presence of a pool of high avidity 582 
cells could explain the persistence of Th1 effectors that would remain activated in the presence 583 
of very low viremia. Such cells may play a key role in viral control, by sensing local "blips" in viral 584 
replication and by triggering a rapid antiviral recall response that would ensure a return to 585 
baseline viremia. The secretion of cytokines by high avidity cells may also help explain the low 586 
grade chronic immune activation that persists in HIV Controllers (6, 30, 58), a phenomenon that 587 
could lead to deleterious consequences in the very long term (14). Future studies should help 588 
determine whether high avidity CD4+ T cells can be detected directly in the peripheral blood of 589 
HIV Controllers, and whether such cells have a phenotype indicative of chronic reactivation. 590 
Another possible explanation for the persistence of Th1 responses in the Controller group may 591 
be the presence of slightly higher levels of residual viral replication in HIV Controllers than in 592 
patients treated in the long term. However, analyses based on high sensitivity viral load assays 593 
have not revealed so far a clearly higher viral burden in the HIV Controller population. 594 
Circulating HIV-1 RNA can be detected in the plasma of most HIV Controllers, but median viral 595 
RNA levels appear extremely low (2 copies/mL) (54). Patients treated in the long term harbor a 596 
residual viremia of the same order of magnitude (1.5 copies/mL) (53). On the other hand, 597 
correlations between viral load and both humoral and cellular responses have been reported in 598 
HIV Controllers (31, 54), suggesting that the availability of viral antigens may influence the level 599 
of recall responses. Thus, it will be important in future studies to determine the respective roles 600 
of antigen levels and antigen sensitivity of T cells in the persistence of Th1 responses in HIV 601 
Controllers. 602 
 603 
Negative immunoregulation may also contribute to the lack of Th1 cytokine production by CD4+ 604 
T cells from treated patients. Prior to therapy initiation, these patients experienced years of 605 
active HIV replication, which inflicted multiple insults to the immune system, including the 606 
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deletion of key populations of CD4+ T cells but also the overstimulation and the exhaustion of 607 
the remaining pool of HIV-specific cells. The expression of inhibitory receptors such as PD-1, 608 
CTLA-4, and TIM-3 is markedly increased on HIV-specific CD4+ T cells of viremic patients, and 609 
is not entirely normalized after therapy, which may limit the capacity of specific CD4+ T cells to 610 
reactivate upon stimulation with HIV antigens (37, 39, 57). It is also noteworthy that IL-10 was 611 
the only cytokine that was more produced by CD4+ T cells in the HAART group than in the HIC 612 
group. The difference was significant for Gag peptides but also, intriguingly, for responses to 613 
CMV peptides. IL-10 production can be viewed as a physiological response contributing to the 614 
containment of excessive Th1 responses. For instance, Th1 cells directly convert to IL-10 615 
producing regulatory T cells in models of tolerance induction (21). In viremic HIV infection, IL-10 616 
is abundantly produced by multiple cell types including monocytes, B cells, and T cells, with 617 
monocytes being major contributors (7, 65). IL-10 causes a reversible impairment of CD4+ T cell 618 
functions such as proliferation and secretion of other cytokines (7, 65, 72). Our findings suggest 619 
that IL-10 production still contributes to the dysfunction of HIV-specific cells in treated HIV 620 
infection, and that negative immunoregulation by IL-10 may also extend to responses against 621 
other pathogens such as CMV. In contrast, HIV Controllers may harbor persistently high levels 622 
of T cell effectors directed against other intracellular pathogens, as suggested by studies 623 
documenting higher CMV-specific CD4 responses (32) and a possibly higher clearance rate of 624 
HCV infection (66) in HIV controllers as compared to uninfected individuals. The persistence of 625 
Th1 effectors directed against HIV may prime the immune system of Controllers for a more 626 
efficient response to other viruses, for instance through a chronic release of IFN-γ that would 627 
facilitate the differentiation of Th1 cells of other specificities though bystander effect. 628 
Alternatively, HIV Controllers may harbor genetic traits that promote Th1 differentiation, which 629 
may be explored in large scale genetic studies. 630 
 631 
 26 
In conclusion, spontaneous HIV control is associated with the persistence of highly functional 632 
Th1 effectors, while pharmacological HIV control leads to a dampening of CD4 effector 633 
functions. The fact that CD4 responses are not entirely lost, but rather dysfunctional, in treated 634 
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LEGEND TO THE FIGURES 959 
 960 
Figure 1: Intracellular cytokine production in patients CD4+ T cells stimulated with Gag 961 
peptides 962 
Intracellular cytokine staining (ICS) was done on PBMC stimulated overnight with the 963 
immunodominant peptides Gag161, Gag263, and Gag293. Cytokine production was evaluated 964 
in the live CD3+ CD4+ population. (A) Examples of ICS in CD4+ T cells from patients stimulated 965 
with Gag293, Gag263, or Gag161. The first 7 plots show the production of TNF-α, MIP-1β, IL-2, 966 
IL-4, IL-17, IL-21, and IL-10 combined with that of IFN-γ. The last plot on the right, second row, 967 
shows the combined expression of total intracellular perforin and of the degranulation marker 968 
CD107a, which was used to determine the cytotoxic potential of CD4+ T cells. The patient ID 969 
and the peptide used for stimulation are indicated above each plot. (B) Quantitation of the 970 
percentage cytokine producing CD4+ T cells detected in HIV Controllers (HIC) and treated 971 
patients (HAART). The summed percentage of cytokine positive cells in response to Gag161, 972 
Gag263, and Gag293 is reported. Horizontal bars indicate median values. Significant P values 973 
(<0.05) obtained with the non parametric Mann-Whitney U test are reported. 974 
 975 
Figure 2: Analysis of intracellular cytokine production to individual Gag and CMV 976 
peptides. 977 
(A en C) The median percentage of cytokine producing cells induced by each of the three 978 
immunodominant Gag peptides is represented in stacked columns (Gag293: grey; Gag263: 979 
black; Gag161: white). (B and D) Cytokine production induced by optimal CMV peptides chosen 980 
in function of patients' HLA DR alleles are represented by hatched bars. Median cytokine 981 
responses that did not reach the detection threshold are represented by the midpoint between 982 
the threshold value of 0.01% and zero (0.005%). Significant differences obtained in the Mann-983 
Whitney U test are indicated by stars: * P<0.05; ** P<0.01.. 984 
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 985 
Figure 3: Polyfunctionality of Gag293-specific CD4+ T cells 986 
(A and B) Polyfunctionality analysis for the CD107a / IFN-γ / IL-2 / MIP-1β / TNF-α panel. Colors 987 
in pie charts represent the proportion of monofunctional cells (dark blue), bifunctional cells (light 988 
blue), trifunctional cells (green), quadrifunctional cells (yellow), and pentafunctional cells 989 
(orange) within the population of Gag293-specific CD4+ T cells, as determined by ICS. The bar 990 
chart shows the frequency of Gag293-specific cells in each functional category, with red bars 991 
corresponding to HIV Controllers (HIC) and dark blue bars corresponding to treated patients 992 
(HAART). *: significant difference in bifunctional cells between the HIC and HAART groups 993 
(P<0.05). 994 
(C and D) Polyfunctionality analysis for the IFN-γ / IL-10 / IL-17/ IL-21 panel. Colors in pie charts 995 
represent the proportion of monofunctional cells (dark blue), bifunctional cells (light blue), 996 
trifunctional cells (green), and quadrifunctional cells (yellow) within the population of Gag293-997 
specific CD4+ T cells. The bar chart shows the frequency of Gag293-specific cells in each 998 
functional category. These analyses were carried out with the SPICE 5.21 program. 999 
 1000 
Figure 4: Detection of Gag293-specific CD4+ T cells by MHC class II tetramer staining. 1001 
(A) Gating strategy to detect Gag293-specific cells in CD4+ T cells. Tetramer staining was 1002 
analyzed in viable CD3+ CD8- CD14- CD19- CD4+ lymphocytes, starting from a minimum of 6 x 1003 
106 PBMC. (B) Examples of detection of Gag293-specific cells with 4 different tetramers based 1004 
on the DRB1*0101, DRB1*0701, DRB1*1101 and DRB5*0101 molecules. For each tetramer, 1005 
the percentage of tetramer-positive (Tet+) cells in CD4+ T cells is indicated for one healthy 1006 
donor (HD), one treated patient (HAART), and one HIV Controller (HIC). A negative control 1007 
consisting in CD4+ T cells labeled with a CLIP-loaded tetramer is shown for each of the HIV 1008 
Controllers tested (HIC-ctrl, right column). 1009 
 1010 
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Figure 5: Frequency and phenotype of Gag293-specific tetramer+ CD4+ T cells in HIV 1011 
Controllers (HIC) and treated patients (HAART). 1012 
(A) The percentage of tetramer-positive (Tet+) CD4+ T cells specific for Gag293 was compared 1013 
in the HIC and HAART groups. (B) The percentage of Tet+ cells specific for optimal CMV pp65 1014 
peptides was compared in the HIC and HAART groups. (C and D) The percentage of central 1015 
memory (CM: CD45RA- CCR7+) and effector memory (EM: CD45RA- CCR7-) CD4+ T cells was 1016 
analyzed in the Gag293 Tet+ population (C) and the CMV Tet+ population (D). (E and F) The 1017 
percentage of CD27+ cells was analyzed in the CM and EM Gag293 Tet+ populations (E) and in 1018 
the CM and EM CMV Tet+ populations (F). (G and H) The percentage of CD38+ cells was 1019 
analyzed in the CM and EM Gag293 Tet+ populations (G) and in the CM and EM CMV Tet+ 1020 
populations (H). Horizontal bars indicate median values. Significant P values (<0.05) obtained 1021 
with the non parametric Mann-Whitney U test are reported. 1022 
 1023 
Figure 6: Correlations between the percentages of Gag293-specific cells detected by 1024 
tetramer staining and by intracellular cytokine staining (ICS). 1025 
(A) Correlation between the percentage of Gag293 tetramer-positiveCD4+ T cells (%Gag293 1026 
Tet+, x axis) and the percentage of IFN-γ secreting CD4+ T cells detected by ICS after Gag293 1027 
stimulation (%IFN-γ+, y axis) in the HIV Controller (HIC) group. (B) Correlation between the 1028 
percentages of Gag293 Tet+ cells and Gag293-specific IFN-γ secreting CD4+ T cells in the 1029 
HAART group. (C) Correlation between the percentages of Gag293 Tet+ cells and Gag293-1030 
specific IL-17-γ secreting CD4+ T cells in the HIC group. (D) Correlation between the 1031 
percentages of Gag293 Tet+ cells and Gag293-specific IL-17-γ secreting CD4+ T cells in the 1032 
HAART group. The non parametric Spearman correlation coefficient R and the P value are 1033 
reported for each correlation. 1034 
____________ 1035 




(HAART, n=16) P value
Age, years 52 [37-69] 49 [35 - 60] N.S.
Duration of HIV-1 infection, years 18 [10 - 28] 18  [10 - 22] N.S.
Duration of antiretroviral treatment, years N/A 10 [10 - 14]  -
Virus load, HIV-1 RNA copies/ml plasma < 40 < 40 N.S.
CD4+ T cells / mm3 754 [315 - 1976] 765 [422 - 1534] N.S.
% CD4+ T cells in CD3+ T cells 53.6 [31.4 - 72.1] 49.9 [15.4 - 79.1] N.S.
Nadir of CD4+ T cells /mm3 N/A 227 [6 - 589]  -
% with HLA B57 or B27 [positive / tested] 65.4 [17 / 26] 10.0 [1 / 10] 0.0036
Median values and range are reported. P values were estimated with the non parametric Mann-Whitney U test. 
N/A: not applicable; N.S.: not significant (P≥0.05).
  
Table 2. Immune activation in CD4+ T cells














        in total T CD4+ 2.5 [1.3-11.9] 3.5 [0.5-18.2] 1.5 [0.9-2.2] N.S. 0.01 0.002
        in naive CD45RA+ CCR7+ T CD4+ 1.2 [0.6-11.0] 1.9 [0.0-6.3] 1.1 [0.3-3.1] N.S. N.S. N.S.
        in CM CD45RA- CCR7+ T CD4+ 1.9 [0.8-5.9] 2.2 [0.4-20.7] 1.4 [0.7-2.9] N.S. N.S. 0.03
        in EM CD45RA- CCR7- T CD4+ 3.8 [1.1-16.4] 5.5 [0.5-11.9] 1.9 [0.7-2.5] N.S. 0.01 0.0005
Median values and range are reported. P values were estimated with the non parametric Mann-Whitney U test. 
CM: central memory; EM: effector memory. N.S.: not significant.
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FSC CD8 / CD14 /CD19 Viability Dye Gag293 Tetramer
Gag293 Tetramer CLIP Tetramer
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Supplementary Figure S1: Control intracellular cytokine staining (ICS) in CD4+ 
T cells from a healthy blood donor
PBMC from a healthy blood donor were either left unstimulated (left) or were stimulated with the 
Gag293 peptide at 5 µg/mL (middle) or with the superantigen SEB at 1 µg/mL (right). CD4+ T 
cells were analyzed for the production of IFN-γ combined with MIP-1β (first row), IL-17 
(second row), IL-10 (third row), and IL-4 (fouth row). The expression of total perforin and of 
the degranulation marker CD107a /LAMP1 was also evaluated (bottom row). Specific staining 
remained undetectable in Gag293 stimulated cells, while significant responses were detected 
after superantigen stimulation. In this example, healthy donor CD4+ T cells stimulated with 
SEB could produce IFN-γ and MIP-1β simulatenously, while IFN-γ and IL-17 stemmed from 
different producer cells. Even after potent antigenic stimulation (SEB), healthy donor cells 
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Supplementary Figure S2: Controls for IL-17 and IL-10 intracellular cytokine staining
Examples of IL-17 and IL-10 responses are shown for one HIV Controller (A) and one treated patient 
(B). Negative controls consisting in unstimulated PBMC are reported in the left column. Stimulated PBMC 
were treated overnight with the Gag293 peptide (middle column) or the Gag263 peptide (right column) at 
a 5 µg/mL concentration. Cytokine responses measured in the live (Aqua-) CD3+ CD4+ population are 
reported. 
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